The Food and Drug Administration granted Breakthrough Therapy Designation to Catalyst Pharmaceuticals Partners Inc.'s (Nasdaq: CPRX) Lambert-Eaton Myasthenic Syndrome treatment Firdapse. The stock price leaped 67 cents to $2.09.
FDA Grants Breakthrough Therapy Designation To Catalyst Pharmaceuticals
August 27, 2013 at 14:38 PM EDT
